Urinary acylcarnitines are altered in human kidney cancer

International Journal of Cancer

Volumn 130, Issue 12, 2012, Pages 2791-2800

  Ganti, Sheila ^a   Taylor, Sandra L ^a   Kim, Kyoungmi ^a   Hoppel, Charles L ^b   Guo, Lining ^c   Yang, Joy ^d   Evans, Christopher ^d   Weiss, Robert H ^a,d,e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c METABOLON INC   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

acylcarnitine; biomarker; fatty acid oxidation; kidney cancer; mass spectrometry; metabolism; metabolomics

Indexed keywords

ACYLCARNITINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GRADING; CHROMATOGRAPHY; CONTROLLED STUDY; DRUG CYTOTOXICITY; EPITHELIUM CELL; HUMAN; HUMAN TISSUE; IN VITRO STUDY; KIDNEY CARCINOMA; MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT; URINALYSIS;

ANIMALS; CARNITINE; CELL LINE, TUMOR; HUMANS; KIDNEY; KIDNEY NEOPLASMS; METABOLOMICS; MICE; NEOPLASM GRADING; NEOPLASM TRANSPLANTATION; NF-KAPPA B; TRANSPLANTATION, HETEROLOGOUS; TUMOR MARKERS, BIOLOGICAL;

EID: 84858050477     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26274     Document Type: Article

References (27)

1. Kim JW, Dang CV,. Cancer's molecular sweet tooth and the Warburg effect. Cancer Res 2006; 66: 8927-8930. (Pubitemid 44521105)
2. Warburg O,. On the origin of cancer cells. Science 1956; 123: 309-314.
3. Derdak Z, Mark NM, Beldi G, Robson SC, Wands JR, Baffy G,. The mitochondrial uncoupling protein-2 promotes chemoresistance in cancer cells. Cancer Res 2008; 68: 2813-2819. (Pubitemid 351556280)
4. Pecqueur C, Bui T, Gelly C, Hauchard J, Barbot C, Bouillaud F, Ricquier D, Miroux B, Thompson CB,. Uncoupling protein-2 controls proliferation by promoting fatty acid oxidation and limiting glycolysis-derived pyruvate utilization. FASEB J 2008; 22: 9-18.
5. Samudio I, Fiegl M, Andreeff M,. Mitochondrial uncoupling and the Warburg effect: molecular basis for the reprogramming of cancer cell metabolism. Cancer Res 2009; 69: 2163-2166.
6. Perroud B, Ishimaru T, Borowsky AD, Weiss RH,. Grade-dependent proteomics characterization of kidney cancer. Mol Cell Proteomics 2009; 8: 971-985.
7. Evans AM, DeHaven CD, Barrett T, Mitchell M, Milgram E,. Integrated, nontargeted ultrahigh performance liquid chromatography/electrospray ionization tandem mass spectrometry platform for the identification and relative quantification of the small-molecule complement of biological systems. Anal Chem 2009; 81: 6656-6667.
8. Minkler PE, Ingalls ST, Hoppel CL,. Strategy for the isolation, derivatization, chromatographic separation, and detection of carnitine and acylcarnitines. Anal Chem 2005; 77: 1448-1457. (Pubitemid 40327886)
9. Minkler PE, Stoll MS, Ingalls ST, Yang S, Kerner J, Hoppel CL,. Quantification of carnitine and acylcarnitines in biological matrices by HPLC electrospray ionization-mass spectrometry. Clin Chem 2008; 54: 1451-1462.
10. Eaton S, Bartlett K, Pourfarzam M,. Mammalian mitochondrial beta-oxidation. Biochem J 1996; 320 (Pt 2): 345-357.
11. Kim K, Aronov P, Zakharkin SO, Anderson D, Perroud B, Thompson IM, Weiss RH,. Urine metabolomics analysis for kidney cancer detection and biomarker discovery. Mol Cell Proteomics 2009; 8: 558-570.
12. Weiss RH, Lin P-Y,. Kidney cancer. Identification of novel targets for therapy. Kidney Int 2006; 69: 224-232.
13. Sanz AB, Sanchez-Nino MD, Ramos AM, Moreno JA, Santamaria B, Ruiz-Ortega M, Egido J, Ortiz A,. NF-kappaB in renal inflammation. J Am Soc Nephrol 2010; 21: 1254-1262.
14. Adams SH, Hoppel CL, Lok KH, Zhao L, Wong SW, Minkler PE, Hwang DH, Newman JW, Garvey WT,. Plasma acylcarnitine profiles suggest incomplete long-chain fatty acid beta-oxidation and altered tricarboxylic acid cycle activity in type 2 diabetic African-American women. J Nutr 2009; 139: 1073-1081.
15. Huang B, Zhao J, Li H, He KL, Chen Y, Chen SH, Mayer L, Unkeless JC, Xiong H,. Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res 2005; 65: 5009-5014. (Pubitemid 40827306)
16. Patole PS, Pawar RD, Lech M, Zecher D, Schmidt H, Segerer S, Ellwart A, Henger A, Kretzler M, Anders HJ,. Expression and regulation of Toll-like receptors in lupus-like immune complex glomerulonephritis of MRL-Fas(lpr) mice. Nephrol Dial Transplant 2006; 21: 3062-3073. (Pubitemid 44567076)
17. Ryan MJ, Johnson G, Kirk J, Fuerstenberg SM, Zager RA, Torok-Storb B,. HK-2: an immortalized proximal tubule epithelial cell line from normal adult human kidney. Kidney Int 1994; 45: 48-57. (Pubitemid 24045991)
18. Kim K, Taylor SL, Ganti S, Guo L, Osier MV, Weiss RH,. Urine metabolomic analysis identifies potential biomarkers and pathogenic pathways in kidney cancer. OMICS 2011; 15: 293-303.
19. Dodson WL, Sachan DS, Krauss S, Hanna W,. Alterations of serum and urinary carnitine profiles in cancer patients: hypothesis of possible significance. J Am Coll Nutr 1989; 8: 133-142. (Pubitemid 20047675)
20. Sachan DS, Dodson WL,. The serum carnitine status of cancer patients. J Am Coll Nutr 1987; 6: 145-150.
21. Wenzel U, Nickel A, Daniel H,. Increased carnitine-dependent fatty acid uptake into mitochondria of human colon cancer cells induces apoptosis. J Nutr 2005; 135: 1510-1514. (Pubitemid 40799619)
22. Zha S, Ferdinandusse S, Hicks JL, Denis S, Dunn TA, Wanders RJ, Luo J, De Marzo AM, Isaacs WB,. Peroxisomal branched chain fatty acid beta-oxidation pathway is upregulated in prostate cancer. Prostate 2005; 63: 316-323. (Pubitemid 40664342)
23. Newgard CB, An J, Bain JR, Muehlbauer MJ, Stevens RD, Lien LF, Haqq AM, Shah SH, Arlotto M, Slentz CA, Rochon J, Gallup D, et al,. A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab 2009; 9: 311-326.
24. Netticadan T, Yu L, Dhalla NS, Panagia V,. Palmitoyl carnitine increases intracellular calcium in adult rat cardiomyocytes. J Mol Cell Cardiol 1999; 31: 1357-1367. (Pubitemid 29335666)
25. Maruyama K, Hara A, Hashizume H, Ushikubi F, Abiko Y,. Ranolazine attenuates palmitoyl-L-carnitine-induced mechanical and metabolic derangement in the isolated, perfused rat heart. J Pharm Pharmacol 2000; 52: 709-715. (Pubitemid 30410085)
26. Wu Y, Song Y, Belardinelli L, Shryock JC,. The late Na+ current (INa) inhibitor ranolazine attenuates effects of palmitoyl-L-carnitine to increase late INa and cause ventricular diastolic dysfunction. J Pharmacol Exp Ther 2009; 330: 550-557.
27. Ng CS, Novick AC, Tannenbaum CS, Bukowski RM, Finke JH,. Mechanisms of immune evasion by renal cell carcinoma: tumor-induced T-lymphocyte apoptosis and NFkappaB suppression. Urology 2002; 59: 9-14. (Pubitemid 34059297)